The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs : a meta-analysis

The notion that the use of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes upon acquisition of coronavirus disease 2019 (COVID-19) should be discredited with a review of the real-life evidence. We aimed to perform a meta-analysis to summarize the risk of mortality with the preadmission/pre-diagnosis use of NSAIDs in patients with COVID-19. A systematic literature search was performed to identify eligible studies in electronic databases. The outcome of interest was the development of a fatal course of COVID-19. Adjusted hazard ratio or odds ratio/relative risk and the corresponding 95% confidence interval from each study were pooled using a random-effects model to produce pooled hazard ratio and pooled odds ratio, along with 95% confidence interval. The meta-analysis of 3 studies with a total of 2414 patients with COVID-19 revealed no difference in the hazard for the development of a fatal course of COVID-19 between NSAID users and non-NSAID users (pooled hazard ratio = 0.86; 95% confidence interval 0.49-1.51). Therefore, NSAIDs should not be avoided in patients who are appropriately indicated during the COVID-19 pandemic.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:29

Enthalten in:

Inflammopharmacology - 29(2021), 3 vom: 21. Juni, Seite 641-644

Sprache:

Englisch

Beteiligte Personen:

Kow, Chia Siang [VerfasserIn]
Hasan, Syed Shahzad [VerfasserIn]

Links:

Volltext

Themen:

Anti-Inflammatory Agents, Non-Steroidal
Journal Article
Meta-Analysis
Review

Anmerkungen:

Date Completed 07.07.2021

Date Revised 07.07.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1007/s10787-021-00810-1

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM324360193